Biotechnology News and Research

RSS

PAREXEL's consolidated service revenue for third-quarter 2010 increases 10.1% to $291.2M

PAREXEL International Corporation today announced its financial results for the third quarter ended March 31, 2010.

From Parexel 28 Apr 2010

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.

28 Apr 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

The Juvenile Diabetes Research Foundation announced today that it is partnering with Living Cell Technologies, a New Zealand-based biotechnology company focused on developing cell based therapeutics, in a Phase II clinical trial to study the safety and effectiveness of transplanting encapsulated insulin-producing cells from pigs as a treatment for type 1 diabetes with significant hypoglycemia unawareness.

28 Apr 2010

MHS announces completion of $7.0 million Series B equity investment

Management Health Solutions, Inc. (MHS), a leading provider of supply chain management solutions to hospitals and healthcare providers across the United States, announced today the completion of a $7.0 million Series B equity investment led by Enhanced Equity Fund, L.P. (Enhanced Equity). Radius Ventures, LLC (Radius), the company's existing institutional investor, also participated in the financing round.

28 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Life Technologies first-quarter non-GAAP 2010 revenue increases 13% to $887 million

Life Technologies Corporation today announced results for its first quarter ending March 31, 2010. Non-GAAP revenue for the first quarter was $887 million, an increase of 13 percent over the $785 million reported for the first quarter of 2009. Excluding the impact of currency and completed acquisitions and divestitures, organic revenue for the quarter grew 10 percent over the same period in the previous year.

28 Apr 2010

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, announced today it has received new advertising approval from Shaanxi State Food and Drug Administration for marketing Xin Aoxing Oleanolic Acid Capsules.

27 Apr 2010

Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI

Pluristem Therapeutics Inc. today announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia, the end-stage of peripheral artery disease. The interim data demonstrated that PLX-PAD is safe, well tolerated and effective.

27 Apr 2010

Pluristem Therapeutics to raise $2.7M through private placement of restricted common stock

Pluristem Therapeutics Inc. today announced that it has entered into definitive agreements with selected investors to sell restricted common stock and warrants for aggregate gross proceeds of approximately $2.7 million. The offering includes 2,420,293 shares of common stock, warrants to purchase 726,088 shares of common stock at an exercise price of $1.25 per share and warrants to purchase 726,088 shares of common stock at an exercise price of $1.40 per share.

27 Apr 2010

Compugen reports revenues of $125,000 for first-quarter 2010

Compugen Ltd. today reported financial results for the first quarter ending March 31, 2010.

27 Apr 2010

DNASTAR, Scarab Genomics announce launch of DNA and RNA sequencing services business

DNASTAR and Scarab Genomics, sister companies founded by genomics pioneer Fred Blattner, announce the launch of a next-generation DNA and RNA sequencing services business. Using their combined expertise, the companies will be offering a full range of sequencing services including library preparation, coordinating the most appropriate sequencing technology and platform, assembly, analysis, annotation, and visualization of end results.

27 Apr 2010

ICON reports net revenues of $219 million for first-quarter 2010

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2010.

27 Apr 2010

Prime-boost malaria vaccine regimen provides sterile protection: Vical

Vical Incorporated announced today that a prime-boost malaria vaccine regimen provided sterile protection, with no disease symptoms and no detectable malaria parasites, in 4 of 15 vaccinated volunteers a full 28 days after challenge with multiple infected-mosquito bites.

27 Apr 2010

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Protalix BioTherapeutics, Inc., announced today it has submitted validation data regarding the Company's manufacturing process for taliglucerase alfa to the U.S. Food and Drug Administration (FDA). The Company made the submission in response to a request from the FDA for validation data from the Company's upgraded manufacturing facility. The FDA is currently reviewing the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease.

27 Apr 2010

Illumina announces shipment of HiScanSQ system for research needs

Illumina, Inc. today announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs.

From Illumina, Inc. 27 Apr 2010

European commission's FP7 programme allocated euro 6.10 billion

Europe is moving towards becoming a knowledge-based economy. Keeping in line with this objective, the European commission has instituted the Framework 7 (FP7) programme. Launched to support the re-launched Lisbon strategy, FP7 focuses on research themes rather than the framework programmes of the past. It has been designed to meet some of the persisting challenges of raising Europe to match global excellence in research, thereby benefiting the European life science funding.

27 Apr 2010

Medivir rights offering to raise approximately SEK 325 million

The Board of Directors has resolved on the terms for the rights offering, that the Board of Directors on 28 March 2010 resolved, subject to approval by the Annual General Meeting. For every share held in Medivir, regardless of share class, the holder is entitled to one subscription right. Four subscription rights entitle the holder to subscribe for one new class B share.

27 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

AES CHEMUNEX to distribute SDIX's RapidChek food pathogen detection systems in Europe

Strategic Diagnostics Inc., now doing business as SDIX, a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic, and food safety applications, today announced it has signed a distribution agreement with AES CHEMUNEX.

27 Apr 2010

SAFC to invest $6.25M for creating 'Center of Excellence' for dry powder media manufacturing

SAFC®, a member of the Sigma-Aldrich® Group, today announced a $6.25 million investment program to expand its Lenexa, KS, facility and create a global 'Center of Excellence' for the seamless upstream and downstream production of dry powder media and reagents. The investment, part of SAFC's worldwide facilities initiative, is designed to better serve the biopharmaceutical industry by creating 'Centers of Excellence' for manufacturing and supply chain optimization.

27 Apr 2010

Biotechnology News and Research

PAREXEL's consolidated service revenue for third-quarter 2010 increases 10.1% to $291.2M

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Phase II clinical trial to test safety and efficacy of transplanted encapsulated islets

MHS announces completion of $7.0 million Series B equity investment

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Life Technologies first-quarter non-GAAP 2010 revenue increases 13% to $887 million

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI

Pluristem Therapeutics to raise $2.7M through private placement of restricted common stock

Compugen reports revenues of $125,000 for first-quarter 2010

DNASTAR, Scarab Genomics announce launch of DNA and RNA sequencing services business

ICON reports net revenues of $219 million for first-quarter 2010

Prime-boost malaria vaccine regimen provides sterile protection: Vical

Protalix BioTherapeutics submits validation data for taliglucerase alfa manufacturing process to the FDA

Illumina announces shipment of HiScanSQ system for research needs

European commission's FP7 programme allocated euro 6.10 billion

Medivir rights offering to raise approximately SEK 325 million

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

AES CHEMUNEX to distribute SDIX's RapidChek food pathogen detection systems in Europe

SAFC to invest $6.25M for creating 'Center of Excellence' for dry powder media manufacturing

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News